收藏切换
A brief introduction to the policy and criteria for conditional approval of innovative anti-tumor drugs in China
收藏切换
PDF
Yue-li QI, Li-min ZOU, Yong-lin JIANG, Ling TANG, Yu DU, Bo-yuan ZHAO, Yan-zhe SUN, Mei-yi XIANG, Zhi-min YANG
Chinese Journal of New Drugs | 2023, 32(2) : 189 - 197
Less
收藏切换
Chinese Journal of New Drugs | 2023, 32(2): 189-197
A brief introduction to the policy and criteria for conditional approval of innovative anti-tumor drugs in China
Full
Yue-li QI, Li-min ZOU, Yong-lin JIANG, Ling TANG, Yu DU, Bo-yuan ZHAO, Yan-zhe SUN, Mei-yi XIANG, Zhi-min YANG
Affiliations
  • Center for Drug Evaluation, National Medicine Products Administration, Beijing 100022, China
Published: 2023-01-30
Outline
收藏切换

In order to encourage clinical value-oriented drug innovation, the current "Drug Registration Regulation" proposes four expedited regulatory approval procedures. For innovative drugs with early clinical trial data that can likely predict the efficacy and clinical benefit of the drugs, the marketing authorization might be granted before the completion of the confirmatory clinical trial through the conditional approval procedure, with all data comprehensively reviewed. By implementing the procedure, patients with serious diseases or conditions can expect more opportunities to prolong their lives or improve their quality of life. Since conditional approval procedures can shorten the time for pre-market clinical research and development, its supporting policies and criteria have attracted much attention. This paper takes the innovative anti-tumor drugs as the starting point, systematically sorts out the policy requirements of conditional approval in China and the criteria that have been formed in the review process, and tries to analyze the problems encountered in the implementation of conditional approval and put forward solutions.

conditional approval  /  innovative drug development  /  tumor
Yue-li QI, Li-min ZOU, Yong-lin JIANG, Ling TANG, Yu DU, Bo-yuan ZHAO, Yan-zhe SUN, Mei-yi XIANG, Zhi-min YANG. A brief introduction to the policy and criteria for conditional approval of innovative anti-tumor drugs in China[J]. Chinese Journal of New Drugs, 2023 , 32 (2) : 189 -197 .
Year 2023 volume 32 Issue 2
PDF
43
16
Cite this Article
BibTeX
Article Info
  • Online Date:2026-03-05
  • Published:2023-01-30
Article Data
Affiliations
History
  • Accepted:2022-11-14
Affiliations
    Center for Drug Evaluation, National Medicine Products Administration, Beijing 100022, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT